The American Society of Hematology (ASH) is the world’s largest professional society serving both clinicians and scientists working in the hematology field with over 17,000 members from almost 100 countries.
Now in its 61st year, the ASH Annual Meeting & Exposition is the most comprehensive hematology event of the year, providing an educational experience and the opportunity to review thousands of scientific abstracts on the newest advancements and important topics in hematology. Attendees are able to network with a global community of over 25,000 hematology professionals.
Journal of Clinical Pathways and Oncology Learning Network were onsite at the meeting to cover the following presentations. Additional session coverage and onsite interviews can be accessed online.
Zanubrutinib Well Tolerated in Patients With Treatment-Naïve CLL
Preliminary results of the SEQUOIA trial indicate that zanubrutinib is active and well tolerated in patients with del(17p) CLL.
Validating the Predictive Value of a Prognostic Indicator in Patients With DLBCL
A neutrophil-to-lymphocyte ratio of at least 4 is further validated as a prognostic tool for predicting lower rates of complete response in patients with diffuse large B-cell lymphoma.
Health Care Costs of CML Therapy vs Other Hematologic Malignancies
Contemporary chronic myelogenous leukemia costs exceed the cost of treatment for other hematologic malignancies, primarily due to the use of tyrosine kinase inhibitors.
Second-Generation TKI Reimbursement for Patients With Chronic-Phase CML
A UK-based real-world study found that for patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia who need at least three lines of therapy, sequencing of tyrosine kinase inhibitors may be determined by drug reimbursement.
Shared Treatment Decision-Making in Lymphoma Patients, Survivors
With the increasing advances and complexity of the lymphoma treatment landscape, patients are seeking to be better informed about treatment options via advocacy organizations and educating themselves through various mediums.
Improving Transfusion Safety and Efficiency for Patients Receiving Daratumumab
Daratumumab’s anti-B lymphocyte properties are therapeutic in multiple myeloma patients; however, it also binds CD38 on erythrocytes and circulates for up to 6 months after a dose.
To effectively delay progression of follicular lymphoma (FL) while maintaining patient quality of life, it is critical that clinicians select therapy for patients with newly diagnosed FL that most optimizes clinical outcomes.
